대한방사성의약품학회지 (Journal of Radiopharmaceuticals and Molecular Probes)

  • 제10권1호
  • /
  • Pages.63-72
  • /
  • 2024
  • /
  • 2384-1583(pISSN)
  • /
  • 2508-3848(eISSN)
대한방사성의약품학회 (Korean Society of Radiopharmaceuticals and Molecular Probes)
권호 표지
DOI QR코드

DOI QR Code

ADC and ARC: The Road to Coexistence

  • In Ho Song (Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital) ;
  • Seung Won Kim (Molim, Inc.)
  • 투고 : 2024.06.12
  • 심사 : 2024.06.24
  • 발행 : 2024.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Recent advances in disease understanding have led to the discovery of new molecular targets and biomarkers. Therapeutic antibodies targeting specific molecules have been successful in the development of antibody-drug conjugates (ADCs) due to their proven clinical effectiveness and manageable toxicity. Antibody-radionuclide conjugates (ARCs), which use radionuclides instead of drugs, also show promise for their potential therapeutic effects in radioimmunotherapy. Identifying these biomarkers before treatment is increasingly important, leading to personalized medicine. Immuno-positron emission tomography (PET) using radiolabeled monoclonal antibodies is promising for non-invasively assessing target expression and distribution. It can provide valuable information for risk assessment, diagnosis, treatment selection, and evaluation of treatment response. This review discusses recent developments in ADC and ARC and aims to explore opportunities for the simultaneous progress of these drugs.

키워드

과제정보

이 논문은 과학기술정보통신부 개인기초연구(2022R1F1A1064049)의 지원에 의하여 이루어졌으며 다른 이해관계는 없음.

참고문헌

  1. The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review.(date accessed); www.antibodysociety.org/antibody-therapeutics-product-data 
  2. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71(20):6300-9. 
  3. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther 2022;7(1):93. 
  4. Kostova V, Desos P, Starck JB, Kotschy A. The Chemistry ́ Behind ADCs. Pharmaceuticals (Basel) 2021;14: 442. 
  5. Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, Kepp O. Trial Watch: experimental TLR7 /TLR8 agonists for oncological indications. Oncoimmunology 2020;9:1796002. 
  6. Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, Palfi A, Muller C, Lutz C, Hechler T, Kulke M, Muller-Tidow C, Kramer A, Goldschmidt H, Pahl A, Raab MS. HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. Mol Cancer Ther 2021;20:367-78. 
  7. Chatal JF, Kraeber-Bodere F, Bodet-Milin C, Rousseau C. Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC)? Current Cancer Therapy Reviews 2016;12(1):54-65. 
  8. Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel) 2021;14:674 
  9. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30(7):631-7. 
  10. Gebleux R, Stringhini M, Casanova R, Soltermann A, Neri D. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int J Cancer 2017;140:1670-9. 
  11. Beck A. Review of antibody-drug conjugates, Methods in molecular biology series: a book edited by Laurent Ducry. MAbs 2014;6:30-3. 
  12. Widel M. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy? Neoplasma 2017;64(5):641-54. 
  13. Pomeroy AE, Schmidt EV, Sorger PK, Palmer AC. Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer 2022;8:915-29. 
  14. Van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007;12:1379-89. 
  15. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 2012;30:3884-92. 
  16. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44(8): 1271-81. 
  17. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc 2010;5(4):739-43. 
  18. Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging 2010;37(2):250-9. 
  19. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48(8):1313-9. 
  20. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 2012;53(1):113-20. 
  21. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schroder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87(5):586-92. 
  22. Natarajan A, Gambhir SS. Radiation dosimetry study of [89Zr]rituximab tracer for clinical translation of B cell NHL imaging using positron emission tomography. Mol Imaging Biol 2015;17(4):539-47. 
  23. Sharma SK, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, Sala E, Zeglis BM, Lewis JS. Preclinical 89Zr immuno-PET of high-grade serous ovarian cancer and lymph node metastasis. J Nucl Med 2016;57(5):771-6. 
  24. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51(8):1293-300. 
  25. Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E, Boerman OC. ImmunoPET imaging of renal cell carcinoma with 124I-and 89Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother Radiopharm 2013;28(7):510-5. 
  26. Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med 2013;54(11):1876-82. 
  27. O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med 2011;52(12):1878-85. 
  28. Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. Eur J Nucl Med Mol Imaging 2023;50(2):287-301. 
  29. Kol A, Fan X, Wazynska MA, van Duijnhoven SMJ, Giesen D, Plat A, Van Eenennaam H, Elsinga PH, Nijman HW, de Bruyn M. Development of 89Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration. J Immunother Cancer 2022;10(12):e004877. 
  30. Miedema IHC, Wijngaarden JE, Pouw JEE, Zwezerijnen GJC, Sebus HJ, Smit E, de Langen AJ, Bahce I, Thiele A, Vugts DJ, Boellaard R, Huisman MC, Menke-van der Houven van Oordt CW. 89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs. Cancers (Basel) 2023;15(23):5546. 
  31. Puyalto A, Rodriguez-Remirez M, Lopez I, Iribarren F, Simon JA, Ecay M, Collantes M, Vilalta-Lacarra A, Francisco-Cruz A, Solorzano JL, Sandiego S, Penuelas I, Calvo A, Ajona D, Gil-Bazo I. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer. Front Immunol 2023;14:1272570. 
  32. Kelly MP, Makonnen S, Hickey C, Arnold TC, Giurleo JT, Tavare R, Danton M, Granados C, Chatterjee I, Dudgeon D, Retter MW, Ma D, Olson WC, Thurston G, Kirshner JR. Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues. J Immunother Cancer 2021;9(1):e002025. 
  33. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50(1):123-31. 
  34. Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt AN, Tinianow JN, Gupta N, Li D, Firestein R, Marik J, Scales SJ, Williams SP. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET. Mol Cancer Ther 2017;16(1):134-42. 
  35. De Bree R, Kuik DJ, Quak JJ, Roos JC, van den Brekel MW, Castelijns JA, van Wagtendonk FW, Greuter H, Snow GB, van Dongen GA. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur J Nucl Med 1998;25(11):1562-5. 
  36. Antibody-Drug Conjugates: A Comprehensive Review. Mol Cancer Res 2020;18 (1): 3-19. 
  37. Antibody Drug Conjugates Report, Evaluate, 2024.2.23. 
  38. ADC Market Will Remain Hot in Oncology, Reaching $30B$30B by 2028: Report, BioSpace, 2024.3.1. 
  39. Berenson A. Market Forces Cited in Lymphoma Drugs' Disuse. New York, NY: New York Times 2007. 
  40. NBC News. Smart-Bomb' Drugs for Lymphoma Underused. New York, NY: NBC News 2007. 
  41. "FDA approves Pluvicto for metastatic castration-resistant prostate cancer", U.S. Food & Drug Administration 2022 
  42. "식약처, 전립선암 환자에 새로운 치료 기회 제공", 식품의약품안전처 보도참고자료 2024 
  43. Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book 2014:e126-31. 
  44. Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. J Clin Oncol 2024;42(7):842-51. 
  45. Ostuni E, Taylor MRG. Commercial and business aspects of alpha radioligand therapeutics. Front Med (Lausanne) 2023;9:1070497.